We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

CerTest Biotec (Zaragoza, Spain) introduced all the new releases developed by the company in recent months, especially its products focused on the diagnosis of SARS-CoV-2, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

Among its new releases highlighted by CerTest at AACC 2021 were the VIASURE Tropical Panel I Real Time PCR Detection Kit designed for the specific and differentiation of Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), West Nile (WNV), Yellow fever (YFV) and/or Mayaro (MYV) viruses; and the FOB Turbilatex non-invasive immunological test for bowel cancer screening.

CerTest’s new products for the diagnosis of SARS-CoV-2 that were exhibited at the event included the CerTest CLIA SARS-CoV-2 Plate which is an antigen detection product; the CerTest SARS-CoV-2 one step card test which is a colored chromatographic immunoassay for the qualitative detection of SARS-CoV-2 from nasopharyngeal swab samples from patients with sign and symptoms of COVID-19 infection; and the VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.

CerTest also used the event as a launching pad for its new Business Units: CerTest CLIA, BioSynProbes and CerTest Vaccines, which were represented at the company’s booth. According to the company, the new business units will complete the portfolio of comprehensive solutions not only for the diagnosis of infectious diseases, but also in the manufacturing processes of clinical tests and disease cure.

Related Links:
CerTest Biotec


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.